>>HAMPTON, N.H., May 3 /PRNewswire/ -- Fisher Scientific International Inc. (NYSE: FSH - news), a world leader in serving science, today announced that it priced a public offering of 12,000,000 shares of the company's common stock at $24.00 per share. The company is selling 11,000,000 shares and stockholders of the company are selling 1,000,000 shares. In addition, the company has granted to the underwriters an option to purchase an additional 1,800,000 shares to cover over allotments.
Fisher Scientific intends to use the net proceeds from the offering for general corporate purposes, including potential acquisitions. The company will not receive any proceeds from shares sold by the selling stockholders. The managing underwriters for the offering are Goldman, Sachs & Co., Credit Suisse First Boston, JPMorgan, Merrill Lynch & Co., and Morgan Stanley. A copy of the prospectus may be obtained from: Goldman, Sachs & Co., 85 Broad Street, New York, N.Y. 10004 (Phone: 212-902-1000). The offering is expected to close on May 9, 2001.
A registration statement relating to these securities was filed and declared effective by the Securities and Exchange Commission. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About Fisher Scientific International Inc.
Fisher Scientific is a world leader in serving science offering more than 600,000 products and services that enable scientific discovery and clinical laboratory testing services to more than 350,000 customers in 145 countries. As a result of its broad product offering, integrated global logistics network and electronic-commerce capabilities, Fisher serves as a ``one-stop source'' of products, services and global solutions for many of its customers. The company's primary target markets are life science, clinical laboratory and industrial-safety supply.<<
snip emphases mine
I'd like to think that FSH's industrial supply biz is less than half of it revenue. This uncertainty has kept me from following FSH more closely. I guess I ought to call IR. Anybody have an educated guess?
Edit: CRL reported last night and -- ahem -- squeaked by estimates:
>>BOSTON, May 2 (Reuters) - Charles River Laboratories International Inc. (NYSE:CRL), which provides rats and mice for drug development and discovery, as well as other related services, said Thursday its first-quarter earnings before items soared thanks in part to strategic acquisitions.
The company said net earnings before extraordinary items totaled $7.2 million, or 18 cents per diluted share, compared with $636,000 and 3 cents a year earlier.
The company's net earnings including a charge for capacity adjustments in Europe were $7 million, or 17 cents per diluted share.
Analysts on average had expected earnings of 16 cents per share, according to research firm Thomson Financial/First Call.
Sales rose 37 percent from the year-earlier period to $99 million.
The company expects second-quarter earnings per share before items of 18 cents to 20 cents on sales of $110 million to $114 million. For the year, the company expects earnings per share in the range of 72 cents to 76 cents.<<
Cheers, Tuck |
